跳至主要内容
临床试验/NCT05298618
NCT05298618已完成不适用

Magnesium Administration After Cardioplegic Arrest With Del Nido Cardioplegia

Children's Hospital Medical Center, Cincinnati1 个研究点 分布在 1 个国家目标入组 152 人开始时间: 2022年1月24日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
152
试验地点
1
主要终点
Examine magnesium levels prior to and after cross-clamp.

研究概览

简要总结

The cardioplegia solution of choice in many pediatric cardiac congenital programs is the del Nido solution. While many cardioplegia solutions provide diastolic arrest, del Nido provides a longer period of time between doses of cardioplegia. Many of the other cardioplegia solutions do not incorporate magnesium into the constituents, but del Nido does. Routine practice at CCHMC is to dose 25 mg/kg magnesium upon removal of the heart cross-clamp to protect against hypomagnesemia and associated arrhythmias. However, with the incorporation of magnesium in the del Nido solution, it may not be necessary to administer magnesium post cross-clamp and it could in fact be detrimental if the magnesium level is too high. This observational study will examine the magnesium levels prior to and after cross-clamp removal under our current process. The magnesium levels measured after the administration of del Nido cardioplegia and prior to cross-clamp removal will help inform our current practice.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Patients undergoing cardiac surgery requiring CPB and cardioplegic arrest with del Nido cardioplegia solution.
  • Patients planned to receive post cross-clamp dose of 25 mg/kg magnesium sulfate.

排除标准

  • 未提供

结局指标

主要结局

Examine magnesium levels prior to and after cross-clamp.

时间窗: 24 months from start of enrollment.

The primary objective of this study is to examine magnesium levels prior to and after cross-clamp.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验